Reneuron Share Discussion Threads

[elgordo] 23/3/2016 11:59

Or the original BBC page

[city chappy] 23/3/2016 11:42

Can anyone point me to a clip on youtube of a man who took Rene's stroke drug and seemed to have made a partial recovery. It was two or three years ago I think.

[noteworthy5] 22/3/2016 11:27

The slide at 7 min 38 sec indicates RENE's Exosome treatment for cancer could go into Phase 1/2 combined and elsewhere he mentions "next year" (2017). Phase 1/2 would yield both safety and efficacy data. However, even a Phase 1 for exosomes would give some indication of efficacy particularly if the results are as obvious as in the preclinical in vitro and in vivo tests when tumour collapse appeared after 18 days.



RENE received a £2.1m grant from Innovate UK in January 2016 (in addition to the placing cash raised last year) to push forward with the pre-clinical work on Exosomes which inturn will help it get it into human trials asap and gives independent validation to the work.

At some point RENE will probably be taken-over by a US pharma.

[dickbush] 22/3/2016 11:12

The last presentation of the "milestones" of product testing showed exosomes entering Phase 1 trials in the first half of 2017 with data available sometime in 2018. I.e only safety will be established during the period the company has current funding for. So, RENE is, apparently, going to need new money to test efficacy. Having said that, if it can demonstrate safety in Phase 1, with the successful results of the tests done already, we should be looking forward to success in the Phase 2 trials, and funding should be easy and at a substantially higher price than currently.

One for patient speculators only.

[dickbush] 22/3/2016 10:44

Phase one trials

Phase one trials aim to test the safety of a new medicine. A small number of people, who may be healthy volunteers, are given the medicine. Researchers test for side effects and calculate what the right dose might be to use in treatment (known as dose-ranging studies).

This will usually be the first time the medicine has been tried on humans, so there's an unavoidable element of risk. To minimise the risk, researchers start with small doses and only increase the dose if the volunteers don't experience any side effects, or if they only experience minor side effects.

Phase two trials

Phase two trials test the new medicine on a larger group of people who are ill. This is to get a better idea of its effects in the short term.

Phase three trials

Phase three trials are only for medicines that have already passed phases one and two.

They test medicines in larger groups of people who are ill, and compare new medicine against an existing treatment or a placebo to see if it's better in practice and if it has important side effects.

Phase three trials often last a year or more and involve several thousand patients.

[noteworthy5] 22/3/2016 10:09

The Wiki entry for British Biotech says it was once capitalised at £2.5 billion mainly on hopes for its anti-cancer tumour drug marimastat and that was almost fifteen years ago since when the market and prices have increased. A cross comparison would put RENE on a minimum of 25 times current valuation merely for its exosome cancer treatment.

Michael Hunt's latest presentation for RENE. 19 minutes 30 sec in there is a slide showing RENE's exosome treatment tested preclinical in cancer tumours.

The graph shows the average results of 5 in vitro studies. After 18 days the tumours collapsed. The photos show the same repeated in vivo (with animals) again resulting in tumour collapse. It basically programs the cancer cells "to die". This could be a major breakthrough.



Add in RENE's treatments for stroke and RP and it could be a fifty bagger.

[horneblower] 21/3/2016 13:30

Thanks 049balt.
I've traded PRM over the years. I'm not sure I trust them. They raise money periodically with great stories of what they can achieve but never seem to deliver fully.
However, they are currently at the bottom of their trading range after a two-phase bear run so maybe they'll haul the share price back to 40p. I'll wait and watch.

[madengland_] 21/3/2016 12:08

Not been in rene for a while. What's the latest action all about anyone? Many thanks

[049balt] 21/3/2016 11:47

HB , another one to have a look at is PRM.

[horneblower] 21/3/2016 11:20

Terrific stuff.
This and Tissue Regenix (TRX) should both be in people's ISA's imo.

Any other Biomedic/genetic co's?

I think the time is getting ripe for the whole industry.

[noteworthy5] 21/3/2016 10:47

Michael Hunt's latest presentation. 19 minutes 30 sec in there is a slide showing the exosome treatment tested preclinical in cancer tumours.

The graph shows the average results of 5 in vitro studies. After 18 days the tumours collapsed. The photos show the same repeated in vivo (with animals) again resulting in tumour collapse. It basically programs the cancer cells "to die".

[norbus] 18/3/2016 11:43

You are deluded.

[noteworthy5] 17/3/2016 16:03

Thoughts on Reneuron's treatment for various variants of retinitis pigmentosa which commenced Phase 1/2 this week.

The market in the USA is currently over 275,000 patients per year. If they treated only 50,000 of those and charged £2000 a shot that produces £100 million per year revenues to Reneuron. If they treat more or charge more the figures would be bigger, e.g. rest of USA, Europe, Japan, rest of world, etc.

It could be filed for marketing as soon as H2 2018 as it is on the fast track route and has special protection for the IP due to the orphan drug status.

[bad robot] 16/3/2016 17:14

Must be his time to look for his dinner by lidl bins. There's competition now, the new gippo on his council estate hves been pouncing on his dinner.

IN BR WE TRUST






Mike111D 16 Mar'16 - 09:38 - 4752 of 4755 0 0 (Filtered)

[bad robot] 16/3/2016 17:10

Traders thread? The little chunts who trades in chunks of fifties. LOL

I do not mingle with lowlife wannabe traders.


I am "the One" , you better stick this in your thick head.


This is BR house and it's BR that will take this orbital in 20p.

Now woman do us our dinner and stay in the kitchen, especially ugly 2 legged woof woof like you


IN BR WE TRUST

[bad robot] 16/3/2016 17:09

LOL
Monkey woman go and play with Banana

Ninja19 is the king, he's the one who put this on mugs radars

[amazon_woman] 16/3/2016 16:53

BR he is a parasite just ignore him he only posted here because I alerted the traders thread to the news !!!! He a stalker lol but too scared to post on our thread

[mike111d] 16/3/2016 09:38

You can still sell at 3.25p if you are quick.

[bad robot] 15/3/2016 21:08

it's time my baby rene goes to 20p

[proactivest] 15/3/2016 14:56

Video interview with Michael Hunt



Michael Hunt, chief financial officer at ReNeuron (LON:RENE), tells Proactive Investors about the US trial where the first human patient suffering from blindness-causing disease, retinitis pigmentosa, was treated using the company's cell therapy candidate.

He hopes ReNeuron's treatment will "at the very least" arrest the deterioration in eyesight caused by the disease and in the best case restore sight.

Hunt hopes to get first data for retinitis pigmentosa Phase I/II US trial before end 2016. Subject to the outcome of this study, he expects ReNeuron to be able to file an application in the second half of 2017 to commence a pivotal Phase II/III clinical trial with its cell therapy candidate.

He says the next significant milestone if all goes well will be the data from its strokes study in a Phase II clinical trial in the UK.

[norbus] 15/3/2016 11:24

noteworthy5 15 Mar'16 - 08:18 - 4740 of 4747 1 0

Rene's fast tracked RP treatment could be filed for market in 2018. Seems like they have another winner on top of the stroke treatments. This is going to be worth billions.

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

You can be sure you will not reap value in billions if it realised Rene will disappear cheapish long before then

As for the share price, I reckon some insiders scared out

[stewart_25] 15/3/2016 10:31

mmm.. strange how the share price moved over the last couple of days prior to the news... onwards and upwards...

[dickbush] 15/3/2016 10:21

noteworthy

RENE has had this exosome news in the public domain for many months, including at peer conferences. So it's no secret. They have also said that it is just at a very early stage of investigation and is the last in order of its product developments. Typical of jam tomorrow stocks, the best jam is the furthest away. This MAY be a big winner, as I hope, but it may be nothing but a highly paid jolly for certain directors. Having said all that, I have a lot of faith in the Chairman whose record in the industry is first class. He is, though, non-exec and I believe his holding is only one million shares. A £30,000 investment is hardly a major act of faith.

[noteworthy5] 15/3/2016 09:54

No wonder Neil Woodford raised his stake in Rene to 20% last year.